What's new

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Mar 17, 2025 - 15:10
 0
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Read More

Tags:

Previous Article

AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

Next Article

PepsiCo to acquire poppi

Related Posts

Human medicines European public assessment report (EPAR): Repaglinide Teva, repaglinide, Date of authorisation: 28/06/2009, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025  0

EMEA-003472-PIP01-23

EMEA-003472-PIP01-23

Feb 17, 2025  0

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0